Skip to content

Start investing now

Invest directly by choosing one of the brokers below

Ameritrade Robinhood New call-to-action New call-to-action Etrade Charles Schwab

Start investing now

Invest directly by choosing one of the brokers below

Ameritrade Robinhood New call-to-action New call-to-action Etrade Charles Schwab

HRTS Cardiovascular and Metabolic ETF

Addressing the metabolic and heart disease epidemic

5 Reasons to Consider

Underpenetrated, large market icon

Underpenetrated, large market

Obesity is forecast to affect one in four people globally by 2035, and obesity-related conditions like diabetes and heart disease represent vast markets with significant growth potential.

Source: World Obesity Atlas, March 2023.

Innovation icon


The Industry is witnessing significant progress in obesity therapeutics led by new drugs such as Ozempic and Wegovy, as well as a renaissance in cardiovascular therapies through novel platforms like gene editing.
Research expertise icon

Research expertise

The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations.
Barriers to entry icon

Barriers to entry

In our view, many of the businesses identified have high barriers to entry, such as such as costly and lengthy clinical trials, large salesforce requirements in primary care markets, and substantial patent protection.
Uncorrelated icon


Performance of many companies relies on clinical or commercial success, which is an uncorrelated source of return.

Fund Overview

Fund Details

As of December 6, 2023
  • Primary Exchange Nasdaq
  • Ticker HRTS
  • Cusip 87975E883
  • Median Bid/Ask Spread (30 Day) 0.38%
  • Fund Inception Date November 20, 2023
  • Gross Expense Ratio 0.99%
  • Net Expense Ratio 0.75%
  • Shares Outstanding 470,000
  • Number of Holdings 42
  • Investment Adviser Tema Global Limited
  • Sub-Investment Adviser NEOS Investments, LLC
  • Distributor Foreside Fund Services, LLC
  • Portfolio Manager David K. Song, MD, PhD, CFA
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/30/2025.

Fund Summary

The actively managed Tema Cardiovascular and Metabolic ETF seeks to provide long-term growth of capital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases. Obesity is on the cusp of a revolution in therapeutics, while heart disease, the most common cause of death, is witnessing a renaissance of therapies driven by genetic insights and tools.

The complex combination of scientific, regulatory and financing risks requires investment and scientific expertise to navigate this secular theme.

Source: Our World in Data, November 2023.

Portfolio Breakdown

Top 10 holdings

As of December 6, 2023
  • Company% Nav

Country Breakdown

Industry Breakdown

Prices & Performance

Monthly Quarterly


3 months


1 Year

3 Years

5 Years

Since Inception

Market Price

As of November 30, 2023December 08, 2023

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.

The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.


HRTS Nav/Market Price

Market Price$27.61
NAV Change (1D)$0.11
Market Price Change (1D)$0.09
Median Bid/Ask Spread (30 Day)0.38%




Ex Date

Record Date

Pay Date



Table Chart

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

How to Buy